According to FutureWise analysis the market for Daratumumab in 2023 is US$ 5.08 billion, and is expected to reach US$ 8.36 billion by 2031 at a CAGR of 6.42%.
Daratumumab is an anti-cancer monoclonal antibody medication sold under the brand name Darzalex. The antibody binds to CD38, which is overexpressed in multiple myeloma cells. As well as binding to CD38 on red blood cells, daratumumab can interfere with routine tests for clinically significant antibodies. A panreactive antibody panel, including a positive auto-control, can mask the presence of clinically significant antibodies. It is effective to negate daratumumab's binding to CD38 on red blood cells by treating them with dithiothreitol (DTT) and repeating the test; however, DTT disrupts disulfide bonds on the surface of red blood cells, which inactivates/destroys many antigens. When urgent transfusion is required, crossmatching with K-negative RBCs is a reasonable alternative to testing with an antigen system associated with common, clinically significant antibodies.
Therefore, a baseline antibody screen and Rh Kell phenotyping (type and screen) should be performed before starting treatment. During therapy, phenotype-matched transfusions should be used if the antibody screen is negative. Positive antibody screens should be given blood that does not contain specific antigens. Daratumumab (brand name: Darzalex) is a monoclonal antibody that targets overexpressed glycoprotein on myeloma cells. Cluster of differentiation 38 (CD38) is the name of this glycoprotein. Medications such as Darzalex are used in the treatment of myeloma as anti-cancer drugs. The CD38 on the red blood cell (RBC) is the site where it binds. There is a possibility that daratumumab could interfere with routine testing for clinically significant antibodies. The presence of any clinically significant antibodies in people with pancreatic antibodies will negate the binding of daratumumab to CD38 on the surface of RBCs. The human monoclonal antibody daratumumab targets CD38, a member of the lectin family of cell surface molecules. CD38 is an antigen found on malignant plasma cells in multiple myeloma patients that binds to it with high affinity and specificity.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Daratumumab Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Daratumumab Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.